Ikonisys SA (ALIKO) - Total Assets
Based on the latest financial reports, Ikonisys SA (ALIKO) holds total assets worth €26.54 Million EUR (≈ $31.02 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Ikonisys SA balance sheet independence to measure how much of total assets are equity-financed.
Ikonisys SA - Total Assets Trend (2019–2024)
This chart illustrates how Ikonisys SA's total assets have evolved over time, based on quarterly financial data. Check Ikonisys SA (ALIKO) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Ikonisys SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Ikonisys SA's total assets of €26.54 Million consist of 6.1% current assets and 93.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0.1% |
| Accounts Receivable | €650.98K | 2.4% |
| Inventory | €688.59K | 2.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €3.30 Million | 12.0% |
| Goodwill | €21.96 Million | 80.2% |
Asset Composition Trend (2019–2024)
This chart illustrates how Ikonisys SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ALIKO company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ikonisys SA's current assets represent 6.1% of total assets in 2024, an increase from 2.6% in 2019.
- Cash Position: Cash and equivalents constituted 0.1% of total assets in 2024, down from 2.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 92.0% of total assets, a decrease from 96.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 80.2% of total assets.
Ikonisys SA Competitors by Total Assets
Key competitors of Ikonisys SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Inspire Medical Systems Inc
NYSE:INSP
|
USA | $911.38 Million |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $90.55 Million |
|
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186
|
China | CN¥1.59 Billion |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
|
China | CN¥805.10 Million |
|
Stratec SE
XETRA:SBS
|
Germany | €443.38 Million |
|
Scandinavian Medical Solutions AS
CO:SMSMED
|
Denmark | Dkr205.86 Million |
|
Duearity AB
ST:DEAR
|
Sweden | Skr10.84 Million |
Ikonisys SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.52 | 0.64 | 0.07 |
| Quick Ratio | 0.28 | 0.26 | 0.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-1.36 Million | €-875.45K | €-1.83 Million |
Ikonisys SA - Advanced Valuation Insights
This section examines the relationship between Ikonisys SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.12 |
| Latest Market Cap to Assets Ratio | 0.78 |
| Asset Growth Rate (YoY) | 31.4% |
| Total Assets | €27.40 Million |
| Market Capitalization | $21.30 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ikonisys SA's assets below their book value (0.78x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Ikonisys SA's assets grew by 31.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Ikonisys SA (2019–2024)
The table below shows the annual total assets of Ikonisys SA from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €27.40 Million ≈ $32.03 Million |
+31.37% |
| 2023-12-31 | €20.85 Million ≈ $24.38 Million |
-3.97% |
| 2022-12-31 | €21.72 Million ≈ $25.39 Million |
-3.57% |
| 2021-12-31 | €22.52 Million ≈ $26.33 Million |
+178.54% |
| 2020-12-31 | €8.08 Million ≈ $9.45 Million |
-0.57% |
| 2019-12-31 | €8.13 Million ≈ $9.51 Million |
-- |
About Ikonisys SA
Ikonisys S.A., a cell-based diagnostics company, develops, produces, and markets medical diagnostic products for early and accurate detection of cancer diseases in the United States and Europe. It offers Ikoniscope Robotic Microscopes, including Ikoniscope20 that provides automated slide handling, slide scanning, and real-time image capture and analysis; and Ikoniscope20max that automates the flu… Read more